Fludarabine and Melphalan: Clinical Trials

3 trials of Fludarabine and Melphalan, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 enrolling by invitation, 1 recruiting, 1 terminated. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Enrolling by invitation 1, Recruiting 1, Terminated 1

Follow Fludarabine and Melphalan: new trials by email Literature Review of Fludarabine and Melphalan trials Research Report on Fludarabine and Melphalan

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
Venetoclax in combination with fludarabine and melphalan, Fludarabine and Melphalan - Venentoclax, Myeloid Malignancies
Phase 3RecruitingFirst Affiliated Hospital of Zhejiang University1862026-03-012026-03-17
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Fludarabine and Busulfan, Fludarabine and Melphalan - Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS)
Phase 3Enrolling by invitationUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology2002023-02-152025-02-10
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)
Fludarabine and Busulfan, Fludarabine and Melphalan, Busulfan and Fludarabine - Leukemia, Myelocytic, Acute
Phase 3TerminatedMedical College of Wisconsin2722011-06-012023-01-04

Conditions studied

Leukemia, Myeloid, Acute (2)  ·  Myelodysplastic Syndromes (2)

Sponsors

First Affiliated Hospital of Zhejiang University (1)  ·  Medical College of Wisconsin (1)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)

Countries

China (2)  ·  United States (1)

Top investigators

Linghui Xia, Professor (1)  ·  Mary Horowitz, MD (1)

Results publications

PMID 28380315

NIH funding

U01HL069294 (1), U24CA076518 (1)